Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.

ABSTRACT:

Background

Re-irradiation for recurrent gliomas is a controversial treatment option with no clear standard dose or concurrent systemic therapy.

Methods

This series represents a single-institution retrospective review of patients treated with re-irradiation for recurrent high-grade glioma. After 2012, patients were commonly offered concurrent bevacizumab as a cytoprotective agent against radiation necrosis. Kaplan-Meier method was used to estimate overall survival and progression-free survival. Cox proportional hazards regression was used to identify factors associated with overall survival and progression-free survival.

Results

Between 2001 and 2021, 52 patients underwent re-irradiation for a diagnosis of recurrent high-grade glioma. 36 patients (69.2%) had a histolog

SUBMITTER: Helis CA 

PROVIDER: S-EPMC9476990 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature